Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited

Regeneron vs. Teva: A Decade of Cost Dynamics

__timestampRegeneron Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20142050180009216000000
Thursday, January 1, 20153927090008296000000
Friday, January 1, 201629969400010044000000
Sunday, January 1, 201739706100011560000000
Monday, January 1, 201843410000010558000000
Tuesday, January 1, 20197822000009351000000
Wednesday, January 1, 202011199000008933000000
Friday, January 1, 202124375000008284000000
Saturday, January 1, 202215604000007952000000
Sunday, January 1, 202318158000008200000000
Monday, January 1, 202419705000008480000000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue Trends: Regeneron vs. Teva

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited have shown contrasting trends in their cost of revenue. Regeneron has seen a remarkable increase, with costs rising by approximately 785% over the decade, peaking in 2021. This surge reflects their aggressive expansion and investment in innovative therapies. In contrast, Teva's cost of revenue has decreased by about 14% during the same period, indicating a strategic shift towards cost efficiency and possibly restructuring efforts.

These trends highlight the differing strategies of these pharmaceutical giants. Regeneron's focus on growth and innovation contrasts with Teva's emphasis on streamlining operations. As the industry faces challenges like patent cliffs and regulatory changes, these insights provide a window into how companies adapt to maintain competitiveness.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025